Filter By Topic75th AnniversaryFamily MattersFitness & NutritionHemophilia A&BInsuranceNovel TechnologiesWomen's Bleeding DisordersBlood SafetyCarriersChapter RoundupGeneration NextHepatitis CSurgery & TransplantsTaking ChargeAdults & AgingAdvocacyHIVNHF in ActionPain ManagementResearcher ProfilesAlternative TreatmentsAsk a Social WorkerCommunity in ActionHemAware JuniorRare Bleeding DisordersGlobal FocusVon Willebrand DiseaseMy JourneySponsored ContentLifeMind & BodyWomen's HealthBleeding Disorders A-ZResearch & TreatmentFighting for YouCommunity Pulse El programa de becas de investigación posdoctoral Judith Graham Pool apoya los avances futuros de la investigación de la hemofilia Si bien hoy en día el nombre Judith Graham Pool puede no ser inmediatamente reconocible para muchas personas en la... Read More Novel Technologies NHF's JGP Program Supports Research Breakthroughs All of the funding for the JGP program comes from donations from NHF chapters and individuals. Read More Novel Technologies Nuevos tratamientos de hemofilia: Inyección subcutánea Pincharse la vena o la de un aterrado niño pequeño no es la forma ideal de administrar el factor. Además... Read More Novel Technologies El poder de las pruebas genéticas para la hemofilia My Life, Our Future (MLOF) es una campaña nacional que ofrece la realización de pruebas genéticas y de genotipificación gratuitas... Read More Novel Technologies La genoterapia para la hemofilia alcanza la madurez Un grupo internacional de más de 100 investigadores que estudian la hemofilia se reunieron el 21 y 22 de octubre... Read More Novel Technologies New Hemophilia Treatments: Subcutaneous Injection Two subcutaneous therapies are currently being investigated. Read More Novel Technologies The Power of Genetic Testing for Hemophilia MLOF is open to all people with hemophilia A and B. Read More Novel Technologies Hemophilia Gene Therapy Comes of Age More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia. Read More Novel Technologies Six at a Time Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6. Read More Novel Technologies Well-Grounded Guideline The comprehensive care model is ideal for people with hemophilia. Read More Hemophilia A&B, Von Willebrand Disease Groundbreaking Guideline These guidelines help ensure patients with hemophilia receive the right care, delivered in the right way. Read More Hemophilia A&B Breaking Down Barriers There are more than 400 different languages spoken in the US. While English is considered the primary language for most... Read More Mind & Body Load More
